CAN
TVRD

Claraphi Advisory Network’s Tvardi Therapeutics TVRD Stock Holding History

Claraphi Advisory Network’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10
Closed -$5K – 1232
2020
Q1 		$5K Buy
+10
New +$5.43K ﹤0.01% 899

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Claraphi Advisory Network's TVRD Position: Q2 2020 in Review

Claraphi Advisory Network sold out of Tvardi Therapeutics (TVRD) in Q2 2020, closing a stake of 10 shares — an estimated $5K sold.

Claraphi Advisory Network first reported a position in TVRD in Q1 2020 and held it in 1 quarter. The position peaked at $5K in Q1 2020. 145 funds tracked by Wall St. Rank hold TVRD as of Q2 2020.

  • Claraphi Advisory Network reported no remaining Tvardi Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Claraphi Advisory Network sold 10 Tvardi Therapeutics shares in Q2 2020, an estimated $5K.
  • Claraphi Advisory Network first reported a position in Tvardi Therapeutics in Q1 2020 and held it in 1 quarter.
  • Claraphi Advisory Network's Tvardi Therapeutics position peaked at $5K in Q1 2020.
  • 145 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2020.

Based on Claraphi Advisory Network's 13F filing for Q2 2020, filed 14 Aug 2020.